← All trials
NCT03309501
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 12, 2017
- Primary completion
- Dec 20, 2019
- Completion date
- Sep 20, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 2000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai University of Traditional Chinese MedicineLead sponsor
- Nanjing Medical UniversityCollaborator
- Shanghai UniversityOverall official - principal investigator
- Shanghai University of Traditional Chinese MedicineReponsible party - principal investigator
- Hubei University of Chinese MedicineCollaborator
- Liaoning Hospital of Traditional Chinese MedicineCollaborator
- Luoyang Osteopathy hospital of HenanCollaborator
- Suzhou Hospital of Traditional Chinese MedicineCollaborator
- The Fourth Central Hospital of TianjinCollaborator
- Wuhan UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.